Perlara PBC Announces Pharma Collaboration with Novartis

One Bench at a Time

Perlara PBC Announces Pharma Collaboration with Novartis

SAN FRANCISCO, Oct. 19, 2016 /PRNewswire/
Perlara PBC (previously Perlstein Lab PBC) today announced the formation of a drug discovery and development collaboration with Novartis to identify new definitive therapeutics for lysosomal storage disorders, starting with lead program Niemann-Pick Type C Disease. In addition to the collaboration, Novartis has made an equity investment in the company. Financial terms are not disclosed.

“Our expertise in whole-animal phenotypic screens, model organism genetics and automation is complemented by Novartis’ world-class pathway and chemical biology expertise, clinical experience and global leadership,” said Ethan Perlstein, Ph.D., CEO, Perlara PBC. “We are eager to begin this next chapter so that our platform technology and discovery programs can move faster to our goal of helping patients and families impacted by diseases with high unmet need.”

Read More…

News story in C&E News

Upcoming Event

  • San Carlos Open House

    15:30-18:00
    11/01/2018
    Come to meet MBC BioLabs residents, tour our new space in San Carlos, and hear about our exciting plans for the future. There will be posters from our companies, a live band, and an opportunity to chat with our partners and staff. RSVP In just 4 years, we have helped 116 entrepreneurial teams create fast, focused and frugal biotech companies that have gone on to raise $2.4 billion and counting. With this new facility, we can empower more entrepreneurs with the space and resources they need to tackle world changing science. Come join us in celebrating our newest MBC Biolabs campus and welcome our residents and partners!

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter